Status:

COMPLETED

Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia

Lead Sponsor:

University of California, Los Angeles

Conditions:

Refractory Ventricular Tachycardia

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Single arm, phase Ib/2a dose escalation study with an expansion cohort to determine the maximal tolerated dose (MTD) for stereotactic ablative radiotherapy of targets in the cardiac myocardium and to ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Documented sustained ventricular arrhythmias refractory to or not a suitable candidate for catheter based RFA ablative therapy
  • Documented sustained ventricular arrhythmias refractory to or not a suitable candidate for cardiac sympathetic denervation therapy
  • Documented ventricular arrhythmias refractory to or not a suitable candidate for cardiac transplantation
  • Documented sustained ventricular arrhythmias refractory to or not a suitable candidate for additional medical management
  • ICD in place with documented episodes recurrent VT despite best clinical management previous refusal of ICD with recurrent sustained ventricular arrhythmias
  • If ischemic cardiomyopathy, myocardial infarction occurred more than one month prior to enrollment
  • No history of prior radiotherapy to the chest
  • Prescribed dose must be deliverable using SABR technique
  • Age ≥ 18 years
  • Karnofsky Performance Status (KPS) \> 70
  • If a woman is of childbearing potential, a negative serum pregnancy test must be documented. Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for at least 4 weeks after study treatment.
  • Ability to understand and willingness to sign a written informed consent

Exclusion

    Key Trial Info

    Start Date :

    April 1 2017

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 6 2019

    Estimated Enrollment :

    1 Patients enrolled

    Trial Details

    Trial ID

    NCT03349892

    Start Date

    April 1 2017

    End Date

    August 6 2019

    Last Update

    November 15 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    UCLA Department of Radiation Oncology

    Los Angeles, California, United States, 90095-6951